Editorial: Mycobacterial Glycolipids-Role in Immunomodulation and Targets for Vaccine Development

Front Immunol. 2020 Oct 8:11:603900. doi: 10.3389/fimmu.2020.603900. eCollection 2020.

Gunilla Källenius¹, Jérôme Nigou², Andrea Cooper³, Margarida Correia-Neves^{1

4

5}

¹ Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
² Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Centre national de la recherche scientifique (CNRS), Université Paul Sabatier, Toulouse, France.
³ Leicester Tuberculosis Research Group (LTBRG), Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom.
⁴ Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
⁵ ICVS/Biomaterials, Biodegradables and Biomimetics (3B's), Portugal (PT) Government Associate Laboratory, Braga, Portugal.

No abstract available

Keywords: Mycobacterium leprae; Mycobacterium tuberculosis; Mycobacterium ulcerans; glycolipid; immunomodulation; lipoarabinomannan; vaccine.

Publication types